Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Equity

v3.19.3.a.u2
Consolidated Statement of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Common Stock Dividend Payable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 504 $ 4,231,746 $ (3,859,087) $ 373,163
Balance, shares at Dec. 31, 2017 5,039,033          
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 298,615 common shares of Processa held by Promet 8,000,000 8,000,000
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502 $ 17 2,312,592 2,312,609
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502, shares 172,327          
Issuance of common stock units for cash, net of costs of $308,830 $ 20 2,874,667 2,874,687
Issuance of common stock units for cash, net of costs of $308,830, shares 200,369          
Issuance of common stock units for a future research funding commitment, net of costs of $168,457 $ 11 1,631,532 (1,800,000) (168,457)
Issuance of common stock units for a future research funding commitment, net of costs of $168,457, shares 113,280          
Stock-based compensation 74,063 74,063
Net loss (3,765,047) (3,765,047)
Balance at Dec. 31, 2018 $ 552 19,124,600 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 5,525,009          
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502 $ 2 258,928 258,930
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502, shares 18,107          
Stock-based compensation 510,478 510,478
Payments made by investor for clinical trial costs 900,000 900,000
Pledged shares of common stock forfeited upon revised research funding commitment $ (5) (899,995) 900,000
Pledged shares of common stock forfeited upon revised research funding commitment, shares (56,640)          
Deemed stock dividend due to full ratched anti-dilution adjustment (3) 3
Net loss (3,357,876) (3,357,876)
Balance at Dec. 31, 2019 $ 549 $ 18,994,008 $ 3 $ (10,982,010) $ 8,012,550
Balance, shares at Dec. 31, 2019 5,486,476